BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the launch of Sitavig® (acyclovir Lauriad®) in the United States by its commercial partner, Innocutis Holdings LLC, and the granting of a new U.S. Sitavig® patent by the United States Patent and Trademark Office.
A few weeks after the execution of a licensing agreement between the two companies, Innocutis has begun the promotion of Sitavig® in the U.S. for the treatment of labial herpes to dermatologists and top tier general practitioners.
Herpes labialis is an extremely widespread condition. Between 20% and 40% of the adult population suffer from recurrent cold sores (1), namely from 60 to 120 million people in the U.S., representing a market potential from 400 to 500 million dollars.
“The U.S. launch of Sitavig®, a drug from the R&D of BioAlliance Pharma, confirms once more our know-how in the development and registration of products in the U.S. We are very confident in Innocutis’ sales team commitment and know-how to successfully implement the product on the U.S. market”, commented Pierre Attali, COO of BioAlliance Pharma, in charge of Strategy and Medical Affairs.
“We were looking forward to this launch and our sales force is now deployed throughout the U.S. market to bring Sitavig® to the clinicians and provide patients with a new way to treat labial herpes”, commented Joe Pecora, CEO of Innocutis Holdings LLC.
Moreover, BioAlliance Pharma was recently granted a new U.S. patent covering Sitavig® and strengthening its U.S. protection. This patent completes a patent portfolio of 3 patents already issued and other pending applications, and confers a commercial exclusivity on Sitavig® until December 2029.
(1). Young TB, Rimm EB, D’Alessio DJ. Cross-sectional study of recurrent herpes labialis: prevalence and risk factors. Am J Epidemiol. 1988;127:612-625.